Aptose Biosciences (TSE:APS) has released an update.
Aptose Biosciences, a clinical-stage company specializing in precision oncology treatments, is set to announce its financial results for the fourth quarter and the end of year 2023 on March 26, 2024. This announcement, which will be available after market close, will be followed by a conference call and webcast where a corporate update will also be provided. The company, known for developing oral targeted agents for hematologic malignancies, emphasizes advancements in its clinical-stage kinase inhibitors, tuspetinib and luxeptinib.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
